ClinicalTrials.gg
TerminatedNCT07259564Updated May 22, 2026

A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)

A Phase 2 interventional study of GS3-007a dry suspension and Insulin in Adult Growth Hormone Deficiency (AGHD), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Other

How we know

Why this study was terminated
Adjustment of sponsor's product development strategy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 13 studies in Dwarfism, Pituitary by Changchun GeneScience Pharmaceutical Co., Ltd. — 3 open to participants now, 3 under way, 2 of them phase 3. Dwarfism, Pituitary · Changchun GeneScience Pharmaceutical Co., Ltd..

Enrollment
10th of 13
120 · median 180
Started
2025
with 1 other
Phase 2
3 of 13
none open now
Registered
13th of 13
by date

Among the 13 studies in Dwarfism, Pituitary by Changchun GeneScience Pharmaceutical Co., Ltd., this one is the 10th largest by enrollment, is one of 2 that started in 2025, is one of 3 in phase 2, and was the 13th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 13 studies in Dwarfism, Pituitary by Changchun GeneScience Pharmaceutical Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Dwarfism, Pituitary by Changchun GeneScience Pharmaceutical Co., Ltd., or all of them as a file.
02

Study summary

The GS3-007a Growth Hormone Stimulation Test (GHST) will be compared with the Insulin Tolerance Test (ITT) in an open-label, randomized, three-way crossover trial. The trial will include subjects suspected to have adult growth hormone deficiency (AGHD) and a group of healthy control subjects.

Read the detailed description

Trial subjects will be assigned to groups of descending likelihood of having AGHD:

Group A: High likelihood of AGHD Group B: Intermediate likelihood of AGHD Group C: Low likelihood of AGHD Group D: Healthy control subjects matched to Group A. The sequential of the GHSTs for Group A-C will be determined by randomization. Group D will undergo testing in the same sequence as their matched Group A counterparts Serum growth hormone (GH) concentrations will be measured at predefined time points before and after GHST with GS3-007a or insulin. The peak GH value and diagnostic cut-off for GS3-007a dry suspension will be evaluated using receiver operating characteristic (ROC) curves. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) outcomes were assessed for GS3-007a. The Insulin Tolerance Test (ITT) served as the comparator to determine positive and negative agreement with GS3-007a GHSTs.

03

Conditions studied

  • Adult Growth Hormone Deficiency (AGHD)

Browse trials for

Keywords

  • adult growth hormone deficiency
  • GS3-007a dry suspension
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Suspected AGHD Subjects (Groups A, B, and C):

  • Age ≥ 18 years and ≤ 65 years, male or female.
  • Suspected AGHD, meeting at least one of the following criteria:

    • Congenital structural/gene defects in the hypothalamus or pituitary gland, or
    • History of surgery or radiotherapy in the hypothalamic or pituitary region, or
    • Adult traumatic brain injury (TBI) or central nervous system (CNS) infection, or
    • Confirmed deficiency of at least one pituitary hormone other than growth hormone (GH), or
    • Idiopathic childhood-onset GHD.
  • IGF-1 SDS \< 0.
  • Willing and able to comply with the study procedures and voluntarily sign the form.

Matched Healthy Control Subjects (Group D):

  • Age ≥ 18 years and ≤ 65 years, male or female.
  • Matching criteria with Group A (subjects with highly suspected AGHD):

    1. Sex;
    2. Age;
    3. ;
    4. (If feasible) Estrogen use and administration route (oral, transdermal) in females:

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to growth hormone secretagogues (GHS) or their or known allergy to insulin or its excipients.
  • conditions newly diagnosed within 6 months before screening, making the subject unsuitable for ITT:

    1. Chronic congestive heart failure ( (NYHA) Class III or higher);
    2. Other significant cardiovascular/cerebrovascular diseases, e.g., uncontrolled severe hypertension, severe arrhythmia, stroke or (TIA), or confirmed coronary artery disease;
    3. Traumatic brain injury (TBI).
  • Short-acting GH therapy within 30 days before screening.
  • Long-acting GH therapy within 90 days before screening.
  • GH stimulation test performed within 7 days before the first dose.
  • Abnormal thyroid function during screening, or any adjustment to thyroid hormone replacement therapy dosage prior to the first study dose.
  • Abnormal gonadal function during screening, or any adjustment to testosterone/estrogen replacement therapy dosage prior to the first study dose.
  • Abnormal adrenal function during screening, or any adjustment to replacement therapy dosage prior to the first study dose.
  • Type 1 diabetes diagnosed before screening, or uncontrolled Type 2 diabetes
  • (BMI) ≥40.0 kg/m².
  • Major surgery (e.g., coronary bypass, hepatectomy/nephrectomy, gynecologic surgery) within 6 months before screening.
  • Acute neurological, digestive, respiratory, circulatory, endocrine, or hematologic diseases within 3 months before screening, judged by the investigator to potentially affect drug absorption, distribution, metabolism, excretion (ADME), or safety evaluation.
  • History or current diagnosis of (any type) before screening.
  • (ECG) findings during screening indicating >450 ms, or history of corrected QT interval (QTc) prolongation, or other clinically significant ECG abnormalities, or use of medications known to prolong QTc interval.
  • Sellar region MRI scan during screening showing untreated intracranial tumor growth.
  • History of clinically symptomatic psychiatric disorders persisting at screening.
  • History of Parkinson's disease or epilepsy persisting at screening.
  • Females with positive blood human chorionic gonadotropin (hCG) during screening, or lactating females, or females planning pregnancy from screening through follow-up completion.
  • Liver function abnormalities during screening
  • Use of medications directly affecting pituitary GH secretion or somatostatin-releasing drugs within a period >5 half-lives before first study dose.
  • Use of strong cytochrome P450 family 3 subfamily A member 4/5 (/5) inhibitors or inducers.
  • Participation in any other drug or medical device clinical trial within 1 month prior to screening, or screening occurring within 5 half-lives of the drug (whichever is longer).
  • Unwillingness to use protocol-specified methods
  • Other conditions deemed by the investigator to make the subject unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    GHST Sequence 1

    GS3-007a low dose, GS3-007a high dose, Insulin Tolerance Test

    Drug: GS3-007a dry suspension · Drug: Insulin

  • Experimental
    GHST Sequence 2

    GS3-007a high dose, Insulin Tolerance Test, GS3-007a low dose

    Drug: GS3-007a dry suspension · Drug: Insulin

  • Experimental
    GHST Sequence 3

    Insulin Tolerance Test, GS3-007a low dose, GS3-007a high dose

    Drug: GS3-007a dry suspension · Drug: Insulin

Interventions

  • DrugGS3-007a dry suspension

    GS3-007a dry suspension, low dose body weight, drinking solution, single dose GS3-007a dry suspension, high dose body weight, drinking solution, single dose

    Also known as: GS3-007a

  • Insulin, 0.10 -0.15 U/kg, intravenous injection, single dose

    Also known as: Insulin Tolerance Test (ITT)

06

What researchers measure

Primary outcomes

  1. ROC curves and the area under the curve (AUC) of the ROC curves

    Time frame: up to 120minutes

Secondary outcomes

  1. Youden index of the ROC curve for GS3-007a dry suspension

    Time frame: up to 120minutes

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 22 days

Other outcomes

  1. Concentrations of GS3-007a and its metabolite GS3-017 in suspected AGHD subjects

    Time frame: up to 120minutes

  2. Serum GH concentration in suspected AGHD subjects

    Time frame: up to 120minutes

  3. Positive agreement rate, negative agreement rate, and overall agreement rate between GS3-007a dry suspension and ITT in diagnosing AGHD

    Time frame: up to 120minutes

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100730, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Apr 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Dec 2, 2025
StartActual
Dec 19, 2025
Primary completionActual
Apr 15, 2026
CompletionActual
May 12, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07259564
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Dec 19, 2025
Primary completion
Apr 15, 2026
Completion
May 12, 2026
Last update
May 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion